BioNTech、Moderna与强生正研发针对omicron的疫苗

市场资讯2021-11-30

BioNTech SE、Moderna Inc．与强生正研究调整现有新冠疫苗，使其可预防变异毒株omicron。其中辉瑞的德国合作伙伴BioNTech表示，如有必要，可能在100天内研制出这款疫苗。 BioNTech周一称已经启动研发工作，以便尽快行动。研发新疫苗的几个初始步骤与评估是否需要疫苗的研究是重合的，BioNTech及Moderna均已于上周四关于新毒株的新闻报道出来后启动了这个程序。 ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

JuJulo
2021-12-01
JuJulo
Pfe 加油

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2187308382?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/8063c97727cb21de0867e6829ff807e3","is_english":false,"pubTime":"2021-11-30 07:32","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2187308382","market":"us","top_or_hot":-1,"title":"BioNTech、Moderna与强生正研发针对omicron的疫苗","media":"市场资讯","content":"<div>\n<p>BioNTech SE、Moderna Inc．与强生正研究调整现有新冠疫苗，使其可预防变异毒株omicron。其中辉瑞的德国合作伙伴BioNTech表示，如有必要，可能在100天内研制出这款疫苗。\nBioNTech周一称已经启动研发工作，以便尽快行动。研发新疫苗的几个初始步骤与评估是否需要疫苗的研究是重合的，BioNTech及Moderna均已于上周四关于新毒株的新闻报道出来后启动了这个程序。\n...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202111300001537c5a3ce0&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech、Moderna与强生正研发针对omicron的疫苗</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech、Moderna与强生正研发针对omicron的疫苗\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 07:32 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202111300001537c5a3ce0&s=b><strong>市场资讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech SE、Moderna Inc．与强生正研究调整现有新冠疫苗，使其可预防变异毒株omicron。其中辉瑞的德国合作伙伴BioNTech表示，如有必要，可能在100天内研制出这款疫苗。\nBioNTech周一称已经启动研发工作，以便尽快行动。研发新疫苗的几个初始步骤与评估是否需要疫苗的研究是重合的，BioNTech及Moderna均已于上周四关于新毒株的新闻报道出来后启动了这个程序。\n...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202111300001537c5a3ce0&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202111300001537c5a3ce0&s=b","article_id":"2187308382","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/8063c97727cb21de0867e6829ff807e3"],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202111300001537c5a3ce0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2187308382","pubTimestamp":1638228742,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"BioNTech SE、Moderna Inc．与强生正研究调整现有新冠疫苗，使其可预防变异毒株omicron。其中辉瑞的德国合作伙伴BioNTech表示，如有必要，可能在100天内研制出这款疫苗。BioNTech周一称已经启动研发工作，以便尽快行动。BioNTech、辉瑞和Moderna能够以空前的速度采取行动：这两款疫苗都使用mRNA技术，可以将新疫苗开发时间缩短到数月。BioNTech和Moderna分别表示，几周内应该会确定是否需要调整现有疫苗。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4532":"文艺复兴科技持仓","BK4007":"制药","BK4504":"桥水持仓","PFE":"辉瑞","BK4550":"红杉资本持仓","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","JNJ":"强生","BK4559":"巴菲特持仓","MRNA":"Moderna, Inc.","BK4568":"美国抗疫概念"},"translate_title":"BioNTech, Moderna and Johnson & Johnson are developing vaccines against omicron","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/0f82cae8c53e6cd35d79134955914faa","symbols_score_info":{"JNJ":0.9,"MRNA":0.9,"PFE":0.9},"content_text":"BioNTech SE、Moderna Inc．与强生正研究调整现有新冠疫苗，使其可预防变异毒株omicron。其中辉瑞的德国合作伙伴BioNTech表示，如有必要，可能在100天内研制出这款疫苗。\nBioNTech周一称已经启动研发工作，以便尽快行动。研发新疫苗的几个初始步骤与评估是否需要疫苗的研究是重合的，BioNTech及Moderna均已于上周四关于新毒株的新闻报道出来后启动了这个程序。\n几个月来，制药商一直在为调整疫苗以应对新变异毒株的可能性做准备。BioNTech、辉瑞和Moderna能够以空前的速度采取行动：这两款疫苗都使用mRNA技术，可以将新疫苗开发时间缩短到数月。\n强生疫苗采用了病毒载体技术。该公司称正在测试其加强针受试者的免疫血液成分，以寻找对omicron的应答，同时也在研发一款专门针对该变异毒株的疫苗，必要时将展开人体研究。\n关于新毒株omicron\n截至纽约时间09：47，BioNTech美国存托凭证上涨1.5%，上周五大涨14%；辉瑞上涨1.6%。Moderna一度飙升12.4%。强生接近持平。\nBioNTech和Moderna分别表示，几周内应该会确定是否需要调整现有疫苗。一位发言人称，辉瑞及其合作伙伴几个月前制定了必要时100天内升级疫苗的计划。\nBioNTech称，测试现有疫苗对新毒株效果如何的同时开始研发升级款疫苗属于标准程序，“以免浪费时间，”“实验室测试将提供关于是否需要调整疫苗的更多信息。”\nModerna首席医疗官Paul Burton周日称，已接种疫苗的人仍可获得防护，具体取决于接种时间有多久，目前最好的建议是接种现有疫苗即可。\n阿斯利康上周五表示也在调查新变异毒株。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":609596409,"gmtCreate":1638292660767,"gmtModify":1638292663339,"author":{"id":"4095601774578290","authorId":"4095601774578290","name":"JuJulo","avatar":"https://static.tigerbbs.com/bb473b3f2f568a71516662aa5b0c8320","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4095601774578290","authorIdStr":"4095601774578290"},"htmlText":"Pfe 加油","listText":"Pfe 加油","text":"Pfe 加油","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609596409","repostId":2187308382,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":26,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2187308382"}